Showing results (431-440 of 831) with videos related to
Sort By:
Pageof 84
Blood Neoplasia|June 2, 2025
Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemiaOlivia M Depies, Qianqian Guo, Yuan Gao, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 8, 2008
Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphomaJames R Cerhan, Wen Liu-Mares, Zachary S Fredericksen, et al.Blood|August 2, 2003
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemiaIman Jilani, Susan O'Brien, Taghi Manshuri, et al.Cancer|May 27, 2003
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disordersJorge Cortes, Francis Giles, Susan O'Brien, et al.Cancer|April 25, 2003
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemiaHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal DysfunctionKoji Sasaki, Amit Lahoti, Elias Jabbour, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylateJorge Cortes, Moshe Talpaz, Susan O'Brien, et al.Clinical Lymphoma, Myeloma & Leukemia|September 25, 2013
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trialsMusa Yilmaz, Hagop Kantarjian, Elias Jabbour, et al.Cancers|March 13, 2024
Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient CareMary Ann Anderson, Renata Walewska, Fidelma Hackett, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2009
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndromeHagop Kantarjian, Guillermo Garcia-Manero, Susan O'Brien, et al.Pageof 84